ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 600

Low Rates of Major Adverse Cardiac Events, Malignancies, and Serious Infections in Subjects with Psoriasis and Psoriatic Arthritis Treated with Apremilast for ≥156 Weeks: Pooled Analysis from the Esteem and Palace 1-3 Phase 3 Trials

Arthur Kavanaugh1, Matthias Augustin2, Eric Lespessailles3, Kim A. Papp4, Maria Paris5, Rongdean Chen5, Dafna D Gladman6, David M. Pariser7 and Ketty Peris8, 1University of California, San Diego, School of Medicine, La Jolla, CA, 2Institute for Health Care Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 3University of Orleans, Orleans, France, 4Probity Medical Research, Waterloo, ON, Canada, 5Celgene Corporation, Summit, NJ, 6Toronto Western Hospital, Toronto, ON, Canada, 7Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, 8Catholic University of Rome, Rome, Italy

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Apremilast (APR), an oral PDE4 inhibitor, was effective in phase 3, randomized, placebo (PBO)-controlled trials assessing treatment of moderate to severe plaque psoriasis (ESTEEM 1 and 2) and psoriatic arthritis (PsA; PALACE 1-3). We report MACE, malignancies, and serious infections (SIs; opportunistic and non-opportunistic) incidences in subjects receiving APR 30 mg BID (APR30) for ≥156 wks in a pooled analysis of these studies.

Methods: Incidence rates and exposure-adjusted incidence rates (EAIR)/100 subject-yrs of MACE, malignancies, SIs, and serious opportunistic infections (SOIs) are reported for 0 to 16 wks, 0 to ≤52 wks, and the APR-exposure period (0 to ≥156 wks) for subjects receiving APR30 any time during the studies, through February 2015; ~30% (n=575) of sbjs received >3 yrs (>156 wks) of APR exposure.

Results: 2,242 subjects were included in the safety analysis for 0 to 16 wks (PBO n=913, subject-yrs exposure [sy]=260.2; APR30 n=1,329, sy=377.8); 1,905 subjects received APR30 during the APR-exposure period, representing 3,527.5 sy. Exposure during 0 to ≤52 wks was 1,524.5 sy. At baseline, 64.2% of APR30 subjects with PsA (PALACE 1-3) were receiving concomitant DMARDs (including methotrexate). Incidence of MACE with APR30 was low and comparable to PBO during 0 to 16 wks. During 0 to ≤52 wks and the APR-exposure period, incidence of MACE (EAIR/100 subject-yrs) remained low (Table). Incidence rates (EAIR/100 subject-yrs) of hematologic malignancies, nonmelanoma skin cancers, and solid tumors were similar with PBO (0.0, 1.2, 0.4) and APR30 (0.0, 1.3, 0.3) during 0 to 16 wks; incidence rates remained low during 0 to ≤52 wks and the APR-exposure period (Table). During 0 to 16 wks, the overall rate of SIs and non-SIs was low and comparable between subjects receiving PBO (20.6%) and APR30 (24.8%). The overall rate of SIs and non-SIs was 42.2% during 0 to ≤52 wks and comparable to rates during the PBO-controlled period (0 to 16 wks); the majority of reported infections (upper respiratory tract infection, nasopharyngitis, sinusitis) were not serious. During the PBO-controlled period (0 to 16 wks), rates of SIs with APR30 were low and comparable to PBO; no SOIs were reported. During 0 to ≤52 wks, the overall rate of SIs was low (0.6%; EAIR/100 subject-yrs: 0.7). The rate of SIs remained low (1.8%; EAIR/100 subject-yrs: 1.0) during the long-term cumulative APR-exposure period (0 to ≥156 wks) (Table). No clustering of any particular event was noted with respect to SIs; most events occurred in only 1 subject. No clinical reactivation of tuberculosis was reported with long-term APR30 exposure (0 to ≥156 wks). The rate of marked hematologic abnormalities remained low with long-term APR exposure.

Conclusion: Incidence of MACE, malignancies, and SIs was low in subjects with psoriasis and PsA receiving APR30 for ≥156 wks. No new safety signals or SOIs were observed over time with APR30.


Disclosure: A. Kavanaugh, Abbott, Amgen, AstraZeneca, BMS, Celgene Corporation, Centocor-Janssen, Pfizer, Roche, UCB, 2; M. Augustin, AbboVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene Corporation, Centocor, Eli Lilly, GSK, Janssen-Cilag, LEO Pharma, Medac, Merck, MSD, Novartis, Pfizer, UCB, XenoPort, 5,AbboVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene Corporation, Centocor, Eli Lilly, GSK, Janssen-Cilag, LEO Pharma, Medac, Merck, MSD, Novartis, Pfizer, UCB, XenoPort, 8; E. Lespessailles, Amgen, Eli Lilly, Novartis, Servier, 2,Amgen, Eli Lilly, Novartis, Servier, 8; K. A. Papp, AbbVie, Akros, Amgen, Astellas, AstraZeneca, Baxalta, Baxter, Boehringer Ingelheim, Bristol-Meyers Squibb, Can-Fite, Celgene, Dermira, Devonian, Dow Pharma, Eli Lilly, Galderma, Genentech, Janssen, Kyowa Hakko Kirin, Leo Pharma, Meiji Seika Pharma, 5,Merck MSD, Merck-Serono, Mitsubishi Pharma, Mylan, Novartis, Pfizer Inc, Regeneron, Roche, Sanofi-Aventis/Genzyme, Takeda, UCB, Valeant, 5,AbbVie, Amgen, Astellas, Celgene, Devonian, Eli Lilly, Galderma, Janssen, Kyowa Hakko Kirin, Leo Pharma, Merck MSD, Novartis, Pfizer Inc, Valeant, 8,Abbvie, Akros, Allergen, Amgen, Anacor, Astellas, Baxalta, Boehringer Ingelheim, Bristol-Meyers Squibb, Celgene, Dermira, Dow Pharma, Eli Lilly, Galderma, Genentech, GSK, Janssen, Kyowa Hakko Kirin, Leo Pharma, MedImmune, Merck MSD, Merck-Serono, Mylan, 2,Novartis, Pfizer Inc, Regeneron, Roche, Sanofi-Aventis/Genzyme, Stiefel, Takeda, UCB, Valeant, 2,AbbVie, Akros, Amgen, Baxter, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Janssen, Kyowa Hakko Kirin, Merck MSD, Merck-Serono, Mitsubishi Pharma, Novartis, Pfizer Inc, Takeda, UCB, Valeant, 9,Akros, Anacor, Kyowa Hakko Kirin, 9,AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Kyowa Hakko Kirin, Merck MSD, Merck-Serono, Novartis, Pfizer Inc, Regeneron, Sanofi-Aventis/Genzyme, Valeant, 9,AbbVie, Amgen, Astellas, Baxter, Boehringer Ingelheim, Bristol-Meyers Squibb, Celgene, Dow Pharma, Eli Lilly, Galderma, Janssen, Merck MSD, Novartis, Pfizer Inc, Regeneron, Sanofi-Aventis/Genzyme, UCB, Valeant, 9; M. Paris, Celgene Corporation, 3; R. Chen, Celgene Corporation, 3; D. D. Gladman, Abbvie, 2,Amgen, 2,Celgene, 2,BMS, 2,Janssen Pharmaceutica Product, L.P., 2,Eli Lilly and Company, 5,Novartis Pharmaceutical Corporation, 2,Pfizer Inc, 2,UCB, 2; D. M. Pariser, Abbott Laboratories, Amgen, Astellas Pharma US, Asubio Pharmaceuticals, Basilea Pharmaceutical, Celgene Corporation, Dow Pharmaceutical Sciences, Eli Lilly, Galderma Laboratories, Graceway Pharmaceuticals, Intendis, Johnson and Johnson, Novartis Pharmaceu, 2,LEO Pharma US and Pfizer, 9; K. Peris, Eli Lilly, LEO Pharma, MEDA, Roche, 9.

To cite this abstract in AMA style:

Kavanaugh A, Augustin M, Lespessailles E, Papp KA, Paris M, Chen R, Gladman DD, Pariser DM, Peris K. Low Rates of Major Adverse Cardiac Events, Malignancies, and Serious Infections in Subjects with Psoriasis and Psoriatic Arthritis Treated with Apremilast for ≥156 Weeks: Pooled Analysis from the Esteem and Palace 1-3 Phase 3 Trials [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/low-rates-of-major-adverse-cardiac-events-malignancies-and-serious-infections-in-subjects-with-psoriasis-and-psoriatic-arthritis-treated-with-apremilast-for-%e2%89%a5156-weeks-pooled-analysis-from/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-rates-of-major-adverse-cardiac-events-malignancies-and-serious-infections-in-subjects-with-psoriasis-and-psoriatic-arthritis-treated-with-apremilast-for-%e2%89%a5156-weeks-pooled-analysis-from/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology